Who are COVID19 convalescent plasma infusion's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/covid19-convalescent-plasma-infusion.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

COVID19 convalescent plasma infusion — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

COVID19 convalescent plasma infusion (COVID19 convalescent plasma infusion) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Passive immunotherapy / Convalescent plasma. Area: Immunology / Infectious Disease.

phase 3 Passive immunotherapy / Convalescent plasma Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

COVID19 convalescent plasma infusion (COVID19 convalescent plasma infusion) — Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno. COVID-19 convalescent plasma infusion transfers antibodies and immune factors from recovered patients to provide passive immunotherapy against SARS-CoV-2.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
COVID19 convalescent plasma infusion TARGET	COVID19 convalescent plasma infusion	Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno	phase 3	Passive immunotherapy / Convalescent plasma

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Passive immunotherapy / Convalescent plasma class)

Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). COVID19 convalescent plasma infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/covid19-convalescent-plasma-infusion. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab